Interest in the use of antibody–drug conjugates (ADCs) for cancer therapy has increased recently, with two approved for clinical use. However, issues with the in vivo stability of the linkers used in many ADCs — based on maleimide-containing components conjugated to reactive thiols — have become apparent. To address this, Lyon et al. incorporated a basic functional group adjacent to the maleimide, which induced the thiosuccinimide ring to undergo rapid hydrolysis, protecting it from maleimide elimination reactions. This 'self-stabilizing' ADC exhibited improved antitumour activity and reduced bone marrow toxicity in mouse lymphoma xenograft models.
References
Lyon, R. P. et al. Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates. Nature Biotechnol. http://dx.doi.org/10.1038/nbt.2968 (2014)
Rights and permissions
About this article
Cite this article
Crunkhorn, S. Increasing stability of ADCs. Nat Rev Drug Discov 13, 812 (2014). https://doi.org/10.1038/nrd4465
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4465